Loading the section
The price of Jazz Pharmaceuticals plc (JAZZ) on October 9, 2026 is 221.01 USD, -0.65% on the day. Over 52 weeks the stock traded between 128.80 USD and 266.38 USD; the price now sits 68% of the way up that range. Over the past year the price changed by +61.99%. The P/E ratio is 463.4, which is above the sector median (24.8). Market capitalization is 13.67 billion USD, rank 18 among 374 stocks of the same industry with a known capitalization.
Prices delayed by 15 minutes
Next earnings report: 04 November 2026 · Earnings calendar
Jazz Pharmaceuticals plc trades on Nasdaq under the ticker JAZZ. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks JAZZ has traded between 128.80 $ and 266.38 $. As of 09 October 2026 the price stood 68.07 % of the way from the 52-week low to the high.
Over one year JAZZ shares rose 61.99 %; over six months they rose 12.27 %. Volatility over 90 days is 28.26 %. Dividends are not included: this is price change only, as of 09 October 2026.
JAZZ trades at a price-to-earnings ratio of 463, above the sector median of 24.8. Price to sales is 3.1, below the sector median of 3.9. Price to book is 3.0, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 228.55 | 229.33 | 214.68 | 222.45 | 1M |
| 07 October 2026 | 229.62 | 235.54 | 227.00 | 231.19 | 578,900 |
| 06 October 2026 | 236.40 | 236.40 | 228.70 | 231.39 | 862,200 |
| 05 October 2026 | 235.51 | 238.87 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Jazz Pharmaceuticals treats narcolepsy and epilepsy and adds oncology drugs to that.
The base is drugs for sleep disorders: a narrow market with few patients, but treatment is lifelong and the medicine is dispensed under a strictly controlled programme, which in itself makes copies hard to introduce. The company managed to move patients onto a new version of the drug before the patent on the old one expired.
The second part is an antiepileptic based on cannabidiol used in children with severe forms. The third is oncology, acquired together with a specialist company. Risks: patent disputes, dependence on a few drugs and execution of its own development. The company pays no dividend.
Address:FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN, D04 E5W7
Jazz Pharmaceuticals plc reported revenue of 4.4B $ and net income of 29M $ over the last four quarters. Net margin is 0.66 %. Revenue changed by +9.20 % year over year. Earnings per share are 0.11 $. Market capitalisation is 13.7B $.
JAZZ has a return on equity of 0.65 %, above the sector median of −41.68 %. Return on assets is 0.25 %, above the sector median of −32.11 %. Operating margin is −0.85 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 234.12 |
| 236.04 |
| 844,600 |
| 02 October 2026 | 233.40 | 237.77 | 231.70 | 235.67 | 636,600 |
| 01 October 2026 | 230.33 | 234.47 | 229.85 | 233.01 | 740,600 |
| 30 September 2026 | 231.60 | 236.00 | 230.39 | 231.52 | 1M |
| 29 September 2026 | 236.30 | 238.00 | 229.16 | 232.35 | 777,200 |
| 28 September 2026 | 235.67 | 238.83 | 234.63 | 238.28 | 788,300 |
| 25 September 2026 | 239.12 | 239.12 | 235.66 | 237.95 | 1M |
| 24 September 2026 | 235.82 | 236.52 | 232.00 | 236.28 | 551,300 |
| 23 September 2026 | 239.26 | 241.33 | 231.59 | 234.88 | 792,200 |
| 22 September 2026 | 242.01 | 243.21 | 239.78 | 240.57 | 482,000 |
| 21 September 2026 | 240.87 | 244.49 | 238.53 | 241.46 | 499,200 |
| 18 September 2026 | 244.55 | 244.55 | 238.98 | 240.74 | 2M |
| 17 September 2026 | 246.59 | 247.31 | 243.57 | 243.84 | 569,600 |
| 16 September 2026 | 242.93 | 244.36 | 241.76 | 243.59 | 602,200 |
| 15 September 2026 | 246.81 | 246.81 | 239.84 | 240.83 | 702,600 |
| 14 September 2026 | 247.68 | 248.45 | 244.66 | 245.87 | 465,400 |
| 11 September 2026 | 244.60 | 246.73 | 244.04 | 245.80 | 422,900 |